Public filings / BBIO on Yahoo Finance (opens in a new tab)
BBIO: insider buying, 13F holders, analyst moves
Bridgebio Pharma Inc
A summary of public filings about Bridgebio Pharma Inc. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
4 of our 100 managers hold BBIO
Combined reported value $1.55B; 1 sold out since Q1 2026.
Holders among our 100 managers: 3 in Q3 2023, 4 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| Farallon Capital | $800.1M | 4.68% | Added |
| Viking Global Investors | $741.0M | 2.11% | Trimmed |
| Tudor Investment | $5.7M | 0.02% | New |
| Polen Capital | $298K | 0.00% | Trimmed |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.